Glucose‐dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity‐associated disorders
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Summary: Glucose‐dependent insulinotropic polypeptide (GIP) is a hormone secreted from the intestinal K‐cells with established insulin‐releasing actions. However, the GIP receptor is widely distributed in peripheral organs, including the adipose tissue, gut, bone and brain, where GIP modulates energy intake, cell metabolism and proliferation, and lipid and glucose metabolism, eventually promoting lipid and glucose storage. In diabetes and obesity, the incretin effect of GIP is blunted, while the extrapancreatic tissues keep a normal sensitivity to this hormone. As GIP levels are normal or elevated in obesity and diabetes, mounting evidence from chemical or genetic GIP deletion in animal models of obesity‐related diabetes suggests that GIP may have a pro‐obesogenic action and that a strategy antagonizing GIP action may be beneficial in these conditions, clearing triglyceride deposits from adipose tissue, liver and muscle, and restoring normal insulin sensitivity. Emerging evidence also suggests that the metabolic benefits of bypass surgery are mediated, at least in part, by surgical removal of GIP‐secreting K‐cells in the upper small intestine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 2×
“Tas1Rs and the coupled G-protein gustducin have been reported in incretin-secreting cells (16), and secretory responses to sweeteners occurred in the GLUTag and NCI-H716 cell lines, while gustducinknock-out animals showed impaired GLP-1 secretion (17).”
BackgroundRoux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985 · cited 1×
“The changes in circulating gut hormones have been advocated at the basis of the beneficial metabolic effects following surgery (135): the rapid delivery of nutrients to the distal small intestine and bowel might up-regulate secretion of GLP-1, which potentiates postprandial insulin release, improves pancreatic b-cell…”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“Resistance to GIP incretin action may also reflect the down-regulation by ubiquitination of the GIP-R on pancreatic b-cells under chronic hyperglycaemia (79,106).”
BackgroundGlucose Sensing in L Cells: A Primary Cell Study
Reimann, F., Habib, A. M., Tolhurst, G., Parker, H. E., Rogers, G. J., & Gribble, F. M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.002 · Cited by 733 · cited 3×
“The generation of transgenic mice expressing this yellow fluorescent protein at the proglucagon or to the GIPpromoter site has allowed identifying individual K-cells in vivo, and helped identify the sodium glucose co-transporter 1 (SGLT-1) and ATP-sensitive K+ channels (KATP) as being important in GIP release (7,8).”
BackgroundLaferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627 · cited 2×
“investigated a possible dys-regulation of incretin secretion or degradation by comparing incretin profiles in healthy lean or obese men after ingestion of a mixed meal or oral glucose; in obese subjects, GLP-1 but not GIP secretion is lower after meal ingestion and oral glucose, whereas GIP but not GLP-1 metabolism is…”
BackgroundHerrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · cited 1×
“investigated a possible dys-regulation of incretin secretion or degradation by comparing incretin profiles in healthy lean or obese men after ingestion of a mixed meal or oral glucose; in obese subjects, GLP-1 but not GIP secretion is lower after meal ingestion and oral glucose, whereas GIP but not GLP-1 metabolism is…”
Background
Cited by
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
Mantelmacher, F. D., Fishman, S., Cohen, K., Pasmanik Chor, M., Yamada, Y., Zvibel, I., & Varol, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601441 · Cited by 27
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Metadata
- Authors
- Paschetta, E., Hvalryg, M., & Musso, G.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2011-08-05
- Volume
- 12
- Issue
- 10
- Pages
- 813-828
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W1599164155
- Cited by
- 32
- References
- 34
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucose‐dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity‐associated disorders. https://app.cochat.ai/papers/10.1111/j.1467-789x.2011.00897.x
- The paper
- Paschetta, E., Hvalryg, M., & Musso, G. (2011). Glucose‐dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity‐associated disorders. Obesity Reviews. https://doi.org/10.1111/j.1467-789x.2011.00897.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.